	US 12,129,495 B2
	Engineered DNA polymerase variants
Ericka Bermudez, Aptos, CA (US); David Elgart, San Mateo, CA (US); Nikki D. Kruse, San Carlos, CA (US); Mathew G. Miller, San Carlos, CA (US); Vesna Mitchell, Santa Clara, CA (US); Jovana Nazor, Milpitas, CA (US); and Nandhitha Subramanian, Cambridge (GB)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Oct. 14, 2022, as Appl. No. 18/046,895.
Claims priority of provisional application 63/256,492, filed on Oct. 15, 2021.
Prior Publication US 2023/0193224 A1, Jun. 22, 2023
Int. Cl. C12N 9/10 (2006.01); C12N 9/12 (2006.01); C12N 15/63 (2006.01)

CPC C12N 9/1252 (2013.01) [C12N 15/63 (2013.01); C12Y 207/07007 (2013.01)]

35 Claims

1. An engineered DNA polymerase, comprising a polypeptide sequence having at least 90%, or more sequence identity to a reference sequence corresponding to residues 12 to 850 of SEQ ID NO: 606, or to a reference sequence corresponding to SEQ ID NO: 606, wherein the polypeptide sequence comprises at least a substitution at amino acid position 40, 85, 102, 132, 157, 177, 262, 263, 503, 748, or 750, or substitution 521G/W/Y, or combinations thereof, relative to the reference sequence corresponding to residues 12 to 850 of SEQ ID NO: 2, or to the reference sequence corresponding to SEQ ID NO: 2.